Literature DB >> 11205368

Imaging axonal damage in multiple sclerosis by means of MR spectroscopy.

N De Stefano1, S Narayanan, M Mortilla, L Guidi, M L Bartolozzi, A Federico, D L Arnold.   

Abstract

Axonal damage in multiple sclerosis has become an important issue. This has been emphasized by recent in vivo proton magnetic resonance (MR) spectroscopy and in vitro pathology studies that have found axonal damage in both lesions and the surrounding normal-appearing white matter. In particular, proton MR spectroscopy, by monitoring levels of N-acetylaspartate (a putative marker of axonal integrity), has been particularly illuminating, as the extent of axonal injury associated with white matter inflammation and demyelination had not been well appreciated from classical pathology studies. Recent MR data demonstrate that cerebral axonal damage begins and contributes to disability from the earliest stages of the disease. This implies that the apparently primary role of axonal damage and loss in the pathogenesis of the disease should be given due importance, and argues for the early treatment of multiple sclerosis with agents directed not only against inflammation, but also towards axonal protection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205368     DOI: 10.1007/s100720070031

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  3 in total

Review 1.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Axonal injury in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 5.081

3.  Occipital proton magnetic resonance spectroscopy (1H-MRS) reveals normal metabolite concentrations in retinal visual field defects.

Authors:  Christine C Boucard; Johannes M Hoogduin; Jeroen van der Grond; Frans W Cornelissen
Journal:  PLoS One       Date:  2007-02-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.